Skip to content

Topiramate-Phentermine Combinations for Cocaine Dependence

Topiramate-Phentermine Combinations for Cocaine Dependence

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02239913
Enrollment
38
Registered
2014-09-15
Start date
2014-09-30
Completion date
2019-09-30
Last updated
2019-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cocaine Use Disorder

Keywords

Cocaine, Pharmacotherapy, Phentermine, Topiramate, Self-Administration

Brief summary

This study will determine the influence of topiramate (Topamax®) and phentermine (Adipex®), alone and in combination, on the reinforcing, subjective and physiological effects of cocaine.

Interventions

DRUGCocaine

The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and topiramate.

DRUGPlacebo

The pharmacodynamic effects of placebo will be determined during maintenance on placebo and topiramate.

DRUGPhentermine

The pharmacodynamic effects of phentermine maintenance will be determined during maintenance on placebo and topiramate.

DRUGTopiramate

The pharmacodynamic effects of chronic topiramate will be determined.

Sponsors

National Institute on Drug Abuse (NIDA)
CollaboratorNIH
University of Kentucky
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* Recent cocaine use by the intranasal or intravenous route

Exclusion criteria

* Abnormal screening outcome (e.g., ECG, blood chemistry result) that study physicians deem clinically significant * Current or past histories of substance abuse or dependence that are deemed by the study physicians to interfere with study completion * History of serious physical disease, current physical disease, impaired cardiovascular functioning, chronic obstructive pulmonary disease, history of seizure or current or past histories of serious psychiatric disorder that in the opinion of the study physician would interfere with study participation will be excluded from participation * Females not currently using effective birth control * Contraindications to cocaine, topiramate or phentermine

Design outcomes

Primary

MeasureTime frameDescription
Reinforcing EffectsNine times over approximately five weeks inpatient admission.The reinforcing effects of cocaine will be determined using a self-administration procedure in which subjects choose to take previously sampled doses.

Secondary

MeasureTime frameDescription
Physiological EffectsDaily over approximately five week inpatient admissionsPhysiological measures will be completed daily while subjects are admitted to our inpatient unit. Physiological measures include temperature, heart rate and blood pressure.
Subjective effectsNine times over approximately five weeks inpatient admission.Subjects will complete subjective effects measures during nine sessions while they are admitted to our inpatient unit. These items will ask about drug effects and general mood.
Side effectsDaily over approximately five weeks of inpatient admissionSubjects will complete a side effects questionnaire daily while they reside on the inpatient unit. Side Effects questions will query subjects about common effects of centrally active medications.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026